DENALI and Biogen Team Up Against LRRK2

DENALI and Biogen Team Up Against LRRK2
The biotech company Denali have announced that they have signed a collaborative deal with the pharmaceutical company Biogen. Together the two companies will co-develop a new class of drug for Parkinson's. LRRK2 is a protein that becomes hyperactive in some cases of Parkinson's and this over-active form of the protein is believed to be associated with the progressive loss of structure ... read more
Source: The Cure Parkinson’s TrustPublished on 2020-08-10